# US 2015/0031706 A1 · Novel compound useful for the treatment of degenerative and inflammatory diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031706 A1
- Document ID: US20150031706A1
- Status: Published application
- Kind: A1
- Application number: 14/457,071
- Filed: 2014-08-11
- Published: 2015-01-29
- Earliest claimed: 2011-04-28
- Assignees: Galapagos NV
- Inventors: Christel Jeanne Marie MENET; Alastair James HODGES; Huw David VATER
- Web page: https://patentgrep.com/patent/US20150031706A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/04: Ortho-condensed systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A pyrazolopyridine compound according to Formula I, able to inhibit JAK is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant JAK activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.

## Claims

### Claim 1

The compound according to Formula I:
or a pharmaceutically acceptable salt, or a solvate, or a solvate of the pharmaceutically acceptable salt, or a biologically active metabolite thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of the compound or pharmaceutically acceptable salt thereof, according to claim 1.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the carrier is selected from a parenteral carrier, an oral carrier and a topical carrier.

### Claim 4 (depends on 2)

The pharmaceutical composition according to claim 2 comprising a further therapeutic agent.

### Claim 5 (depends on 1)

A method for the treatment, or prophylaxis of allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons, comprising administering an amount of a compound or pharmaceutically acceptable salt thereof according to claim 1, sufficient to effect said treatment, or prophylaxis.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the compound or pharmaceutically acceptable salt thereof, is administered in combination with a further therapeutic agent.

### Claim 7 (depends on 2)

A method for the treatment, or prophylaxis of allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons, comprising administering an amount of the pharmaceutical composition of claim 2, sufficient to effect said treatment, or prophylaxis.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the pharmaceutical composition is administered in combination with a further therapeutic agent.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the further therapeutic agent is an agent for the treatment, or prophylaxis of allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

### Claim 10 (depends on 2)

The pharmaceutical composition according to claim 2 comprising a further therapeutic agent selected from arthritis treatment agents.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the further therapeutic agent is an agent selected from analgesics, NSAIDS (non-steroidal anti-inflammatory drugs), and DMARDS (disease-modifying anti-rheumatic drugs).

### Claim 12 (depends on 1)

A method for the treatment of rheumatoid arthritis, comprising administering an amount of a compound of claim 1, sufficient to effect said treatment.

### Claim 13 (depends on 12)

The method according to claim 12, wherein said compound is administered in combination with one or more further therapeutic agents selected from arthritis treatment agents.

### Claim 14 (depends on 12)

The method according to claim 12, wherein said compound is administered in combination with one further therapeutic agent selected from arthritis treatment agents.

### Claim 15 (depends on 2)

A method for the treatment of rheumatoid arthritis, comprising administering an amount of a pharmaceutical composition of claim 2, sufficient to effect said treatment.

### Claim 16 (depends on 4)

A method for the treatment of rheumatoid arthritis, comprising administering an amount of a pharmaceutical composition of claim 4, sufficient to effect said treatment.

### Claim 17 (depends on 15)

The method according to claim 15, wherein said pharmaceutical composition is administered in combination with one or more further therapeutic agents selected from arthritis treatment agents.

### Claim 18 (depends on 15)

The method according to claim 15, wherein said pharmaceutical composition is administered in combination with one further therapeutic agent selected from arthritis treatment agents.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the further therapeutic agent is selected from arthritis treatment agents.

### Claim 20 (depends on 13)

The method according to claim 13, wherein the further therapeutic agent is an agent selected from analgesics, NSAIDS (non-steroidal anti-inflammatory drugs), and DMARDS (disease-modifying anti-rheumatic drugs).

### Claim 21 (depends on 14)

The method according to claim 14, wherein the further therapeutic agent is an agent selected from analgesics, NSAIDS (non-steroidal anti-inflammatory drugs), and DMARDS (disease-modifying anti-rheumatic drugs).

### Claim 22 (depends on 17)

The method according to claim 17, wherein the further therapeutic agent is an agent selected from analgesics, NSAIDS (non-steroidal anti-inflammatory drugs), and DMARDS (disease-modifying anti-rheumatic drugs).

### Claim 23 (depends on 18)

The method according to claim 18, wherein the further therapeutic agent is an agent selected from analgesics, NSAIDS (non-steroidal anti-inflammatory drugs), and DMARDS (disease-modifying anti-rheumatic drugs).

### Claim 24 (depends on 19)

The method according to claim 19, wherein the further therapeutic agent is an agent selected from analgesics, NSAIDS (non-steroidal anti-inflammatory drugs), and DMARDS (disease-modifying anti-rheumatic drugs).
